President & CBO, R-Pharm U.S.
Demetrios Kydonieus is a senior pharmaceutical executive with proven success leading multibillion-dollar global transactions and complex negotiations. He has been instrumental in assisting small, medium and large BioPharma companies in executing their corporate strategies resulting in significant growth and shareholder value.
In 2014, Demetrios teamed up with Mark Pavao to create a differentiated specialty BioPharma company. The opportunity to work with Russia’s premier pharmaceutical company, R-Pharm JSC, presented a unique opportunity to accelerate the growth and importance of the BioPharma start-up (R-PHARM US).
Prior to R-Pharm U.S., Demetrios was the Vice President, Strategy, Alliances and Transactions (SAT) at Bristol Myers Squibb (BMS) where he was instrumental in helping BMS implement the BioPharma transformation and execute the String of Pearls strategy.
Demetrios began working at BMS in 1998 as Director, Worldwide Regulatory Affairs in the Health Care Group. After leaving the Health Care Group, Demetrios joined the Corporate Strategy and Issues Management Group as Director, Business Risk Management, where he identified and helped manage the largest risks to the BMS strategy. Demetrios later moved with his family to Boston to be General Counsel for BMS Medical Imaging, where he was a member of the business unit’s Executive Team and helped lead the divestiture of the business to private equity.
Demetrios earned his Juris Doctor degree from Quinnipiac University School of Law and his Masters of Business Administration from Duke University, Fuqua School of Business.